Tumor Mutation Burden as a Biomarker in Resected NSCLC Tumor Mutation Burden as a Biomarker in Resected NSCLC

Use of tumor mutation burden may help identify patients who can achieve a more pronounced survival benefit from adjuvant chemotherapy for NSCLC.Journal of Clinical Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news